多种肿瘤自身抗体对结直肠癌诊断的应用价值

doi:10.6040/j.issn.1671-7554.0.2019.076

摘要/Abstract

摘要： 目的探究联合检测多种肿瘤相关抗原自身抗体对结直肠癌诊断的应用价值。方法选取2017年5月至11月间收治于山东大学附属省立医院住院部的结直肠癌组、癌前病变组以及对照组血清标本及临床资料,采用酶联免疫吸附实验对纳入人群血清脱嘌呤/脱嘧啶核酸内切酶1(APE1)、微管关联蛋白RP/EB家族成员1(MAPRE1)、纽约食管鳞状细胞癌1(NY-ESO-1)自身抗体进行检测,采用ROC曲线对3种新型自身抗体以及传统指标癌胚抗原(CEA)、糖类抗原-199(CA-199)的诊断效能进行分析。结果 3组APE1 AAbs、MAPRE1 AAbs、NY-ESO-1 AAbs血清水平比较差异有统计学意义(P<0.01),且3种自身抗体的AUC值(0.772,95%CI:0.688~0.856;0.794,95%CI:0.716~0.873;0.854,95% CI:0.778~0.929)高于CA-199(0.571,95%CI:0.477~0.664)。NY-ESO-1 AAbs的AUC高于CEA(0.720,95%CI:0.639~0.801,P<0.05)。NY-ESO-1 AAbs +CEA组合的AUC(0.889, 95%CI:0.829~0.949)高于NY-ESO-1 AAbs(P=0.03),上述差异均有统计学意义。APE1 AAbs+NY-ESO-1 AAbs+CEA组合的AUC为0.927(95%CI:0.885~0.970),与NY-ESO-1 AAbs+CEA组合相比差异具有统计学意义(P=0.04)。结论 APE1 AAbs、NY-ESO-1 AAbs、CEA联合检测可提高结直肠癌的诊断效能,具有临床应用价值。

Abstract: Objective To explore the application value of combined detection of tumor-associated autoantibodies in the diagnosis of colorectal cancer(CRC). Methods The serum specimens and clinical data of CRC patients(CRC group)and precancerous patients(precancerous group)treated in our hospital during May 2017 and November 2017, and the information of healthy controls(control group)were collected. The apurinic/apyrimidinic endonuclease 1(APE1), microtubule associated protein RP/EB family, member 1(MAPRE1)and New York esophageal squamous cell carcinoma 1(NY-ESO-1)autoantibodies levels were detected with enzyme-linked immunosorbent assay(ELISA). The diagnostic efficacies of three autoantibodies and traditional indicators(CEA and CA-199)were analyzed with receiver operating characteristic curve(ROC). Results There were significant differences in the levels of APE1 AAbs, MAPRE1 AAbs and NY-ESO-1 AAbs among the three groups. The area under the curve(AUC)of the 3 autoantibodies(0.772, 95%CI: 0.688-0.856; 0.794, 95%CI: 0.716-0.873; 0.854, 95%CI: 0.778-0.929)were higher than that of CA-199(0.571, 山东大学学报 (医学版)57卷4期 -耿旭,等.多种肿瘤自身抗体对结直肠癌诊断的应用价值 \=-95%CI: 0.477-0.664, P<0.05). The AUC of NY-ESO-1 AAbs was higher than that of CEA(0.720, 95%CI: 0.639-0.801, P<0.05). The AUC of NY-ESO-1 AAbs + CEA(0.889, 95%CI: 0.829-0.949)was higher than that of NY-ESO-1 AAbs (P=0.03). The AUC of APE1 AAbs+NY-ESO-1 AAbs+CEA(0.927, 95%CI: 0.885-0.970)was statistically higher than that of NY-ESO-1 AAbs+CEA (P=0.04). Conclusion The combined detection of APE1 AAbs, NY-ESO-1 AAbs and CEA can significantly improve the diagnostic efficacy of colorectal cancer, and it is worth clinical application.

Key words: Colorectal cancer, Tumor-associated autoantibody, Apurinic/apyrimidinic endonuclease 1, New York esophageal squamous cell carcinoma 1, Diagnostic efficacy

中图分类号:

R446

耿旭,张璐,李明,卢志明. 多种肿瘤自身抗体对结直肠癌诊断的应用价值[J]. 山东大学学报 (医学版), 2019, 57(4): 65-71.

GENG Xu, ZHANG Lu, LI Ming, LU Zhiming. Application value of combined detection of tumor-associated autoantibodies in the diagnosis of colorectal cancer[J]. Journal of Shandong University (Health Sciences), 2019, 57(4): 65-71.

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] 兰蓝, 赵飞, 蔡玥, 等. 中国居民2015年恶性肿瘤死亡率流行病学特征分析[J]. 中华流行病学杂志, 2018, 39(1): 32-34. LAN Lan, ZHAO Fei, CAI Yue, et al. Epidemiological analysis on mortality of cancer in China, 2015[J]. Chinese Journal of Epidemiology, 2018, 39(1): 32-34.
[4] 陈瑞瑞, 梁红, 何夕昆. 结直肠肿瘤的种族差异性研究进展[J]. 山东医药, 2018, 58(18): 96-98.
[5] Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer[J]. Ann Oncol, 2011, 22(2): 383-389.
[6] 李波, 李伯安. 自身抗体检测在原发性肝癌诊断中的意义[J]. 中华检验医学杂志, 2016, 39(2): 76-78. LI Bo, LI Boan. The significance of autoantibodies detection for the diagnosis of primary hepatic carcinoma[J]. Chinese Journal of Laboratory Medicine, 2016, 39(2): 76-78.
[7] Zhang SH, Wang LN, Li Z, et al. APE1 polymorphisms are associated with colorectal cancer susceptibility in Chinese Hans[J]. World J Gastroenterol, 2014, 20(26): 8700-8708.
[8] 何乐, 杨宇馨, 张诗珩, 等. 血清APE1自身抗体在结直肠癌诊断中的价值[J].第三军医大学学报, 2016, 38(11): 1297-1301. HE Le, YANG Yuxin, ZHANG Shiheng, et al. Diagnostic value of serum APE1 autoantibodies in colorectal cancer[J]. Journal of Third Military Medical University, 2016, 38(11): 1297-1301.
[9] Dai N, Cao XJ, Li MX, et al. Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer[J]. PLoS One, 2013, 8(3): e58001. doi:10.1371/journal.pone.00580 01.
[10] Taguchi A, Rho JH, Yan Q, et al. MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas[J]. Cancer Prev Res(Phila), 2015, 8(11): 1112-1119.
[11] Healey GF, Lam S, Boyle P, et al. Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer[J]. J Thorac Dis, 2013, 5(5): 618- 625.
[12] 梁爽, 王晓华, 赵艳明, 等. 直肠癌中肿瘤/睾丸抗原相关基因的表达[J]. 中国实验诊断学, 2011, 15(1): 91-93. LIANG Shuang, WANG Xiaohua, ZHAO Yanming, et al. Expression of cancer-testis antigen-related genes in human colorectal carcinomas[J]. Chinese Journal of Laboratory Diagnosis, 2011, 15(1): 91-93.
[13] Fujiwara S, Wada H, Kawada J, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer[J]. Br J Cancer, 2013, 108(5): 1119-1125.
[14] McKeown E, Nelson DW, Johnson EK, et al. Current approaches and challenges for monitoring treatment response in colon and rectal cancer[J]. J Cancer, 2014, 5(1):31-43.
[15] Goldberg EM, Simunovic LM, Drake SL, et al. Comparison of serum CA 19-9 and CEA levels in a population at high risk for colorectal cancer[J]. Hybridoma, 1989, 8(5): 569-575.
[16] Liu W, Wang P, Li Z, et al. Evaluation of tumour-associated antigen(TAA)miniarray in immunodiagnosis of colon cancer[J]. Scand J Immunol, 2009, 69(1): 57-63.
[17] Fan CW, Kuo YB, Lin GP, et al. Development of a multiplexed tumor- associated autoantibody-based blood test for the detection of colorectal cancer[J]. Clin Chim Acta, 2017, 475: 157-163. doi: 10.1016/j.cca.2017.10.022.
[18] Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues[J]. Int J Cancer, 2001, 92(6): 856-860.
[19] Huajun W, Ying F, Hongxing Z, et al. Clinical value of combined detection of serum APE1-Aabs and CEACAM-1 in the diagnosis of colorectal cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(5): 1286-1289.
[20] 于海跃, 刘正昊, 崔君鹏, 等. APE1基因(Asp148Glu)多态性与结直肠癌易感性之间关系的Meta分析[J]. 临床外科杂志, 2017, 25(10): 41-44. YU Haiyue, LIU Zhenghao, CUI Junpeng, et al. Association between APE1(Asp148Glu)gene polymorphism and colorectal cancer susceptibility: a meta-analysis[J]. Journal of Clinical Surgery, 2017, 25(10): 41-44.
[21] Ladd JJ, Busald T, Johnson MM, et al. Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women[J]. Cancer Prev Res(Phila), 2012, 5(4): 655-664.
[22] Li Y, Song R, Li X, et al. Expression and immunogenicity of NY-ESO-1 in colorectal cancer[J]. Exp Ther Med, 2017, 13(6): 3581-3585.
[23] Chan CC, Fan CW, Kuo YB, et al. Multiple serological biomarkers for colorectal cancer detection[J]. Int J Cancer, 2010, 126(7): 1683-1690.
[24] Baudrin LG, Deleuze JF, How-Kit A. Molecular and computational methods for the detection of microsatellite instability in cancer[J]. Front Oncol, 2018, 8: 621. doi:10.3389/fonc.2018.00621.
[25] Chen W, Frankel WL. A practical guide to biomarkers for the evaluation of colorectal cancer[J]. Mod Pathol,2019. doi: 10.1038/s41379-018-0136-1.

相关文章 15

[1]	孙富云,王维鹏,张会会,耿艳,安小霞,李双双,张彬彬. 结直肠癌术后患者人格特质与抑郁、焦虑症状的关联性[J]. 山东大学学报 (医学版), 2021, 59(7): 91-96.
[2]	杜甜甜,李娟,赵颖慧,段伟丽,王景,王允山,杜鲁涛,王传新. 长链非编码RNA LINC02474在结直肠癌中的表达特征及对细胞增殖的影响[J]. 山东大学学报 (医学版), 2021, 59(10): 57-67.
[3]	肖娟,肖强,丛伟,李婷,丁守銮,张媛,邵纯纯,吴梅,刘佳宁,贾红英. 两种甲状腺超声数据报告系统诊断效能的比较[J]. 山东大学学报 (医学版), 2020, 1(7): 53-59.
[4]	李宁,李娟,谢艳,李培龙,王允山,杜鲁涛,王传新. 长链非编码RNA AL109955.1在80例结直肠癌组织中的表达及对细胞增殖与迁移侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 38-46.
[5]	朱宇,王宏洁,韩彬彬,冯莎娜,张春,李学祥,韩晓红,崔巍. 人异常凝血酶原(PIVKA-II)在监测结直肠癌肝转移中的应用[J]. 山东大学学报 (医学版), 2018, 56(10): 58-63.
[6]	方茜, 曲爱林, 张欣, 杜鲁涛, 杨咏梅, 王传新. 血清miR-210在结直肠癌患者血清中的表达及临床意义[J]. 山东大学学报（医学版）, 2015, 53(6): 77-81.
[7]	刘成霞, 李明, 连海峰, 史宁. miRNA-486-5p对结肠癌细胞株SW620生物学行为的影响[J]. 山东大学学报（医学版）, 2015, 53(1): 16-20.
[8]	李剑萍, 缪宇锋, 陈平, 陈苏蓉, 刘红旗. 雷替曲塞联合奥沙利铂或伊立替康二线治疗晚期结直肠癌的临床观察[J]. 山东大学学报（医学版）, 2014, 52(S1): 49-50.
[9]	张艳丽, 刘新风, 张欣, 王海燕, 杨咏梅, 杜鲁涛, 王丽丽, 李培龙, 王传新. 循环miR-128在结直肠癌患者血清中的表达及其对细胞迁移侵袭能力的影响[J]. 山东大学学报（医学版）, 2014, 52(8): 57-62.
[10]	刘文辉, 李晓玲, 袁萍, 栾荣生, 冯斐, 胡晓琴, 燕锦, 杨艳芳. 脂联素基因和钙蛋白酶10基因多态性与结直肠癌发生风险的关系[J]. 山东大学学报（医学版）, 2014, 52(11): 106-112.
[11]	冯斐1，燕锦2，袁萍1，胡晓琴1，徐琳2，杨艳芳1. 饮食习惯、生活方式与结直肠癌关系的配对病例对照研究[J]. 山东大学学报(医学版), 2013, 51(7): 107-112.
[12]	刘慧，杜鲁涛，杨咏梅，董召刚，李娟，刘益民，张欣，王丽丽，郑桂喜，王传新. MiR-182在结直肠癌中的表达及其对结直肠癌细胞迁移能力的影响[J]. 山东大学学报(医学版), 2013, 51(12): 70-74.
[13]	樊智彬1，于卫芳2,张丽静1，刘博1，吴晨鹏3，张学明4，赵增仁1. microRNA-150在结直肠癌组织中的表达及临床意义[J]. 山东大学学报(医学版), 2013, 51(11): 85-89.
[14]	袁志平1，牟华平2，王秋1，王立帅1，陈洁1，张川利1，周光远1，陈家莲1. VEGF、sICAM-1蛋白在结直肠癌患者血清中的表达水平及临床意义[J]. 山东大学学报(医学版), 2013, 51(10): 74-76.
[15]	赵增仁1，张丽静1，张志勇2，郑峥1，王园园1，孙晓锋1. 结直肠癌中p53、Nup88的表达及其相关性[J]. 山东大学学报(医学版), 2011, 49(4): 105-109.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed